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A B S T R A C T
Lipid and apolipoprotein serum levels as a consequence of excessive nutrition in the overweight individuals with fa-
milial combined hyperlipidemia (FCHL) in comparison with the obese ones are studied only sporadically. In this study,
the effect of overweight and obesity in subjects with FCHL on serum lipids and apolipoproteins was investigated. The
participants were 36 overweight and 10 obese men. 17 normolipidemic healthy men served as the control group. The
mean age of all subjects included was 49±9 years. Lipid and apolipoprotein serum levels were determined by standard
methods. The increased body weight in overweight men with FCHL correlates with increased cholesterol and triacyl-
glycerol serum levels (p<0.001), atherogenous ratio values, apolipoprotein serum levels – apo C-III, apo C-II and apo
B100 (p<0.001) as well as decreased HDL cholesterol serum levels (p<0.05). Lipid metabolism in men with FCHL is dete-
riorated by a high energy intake and its low output. The overweight and not only obesity, in association with FCHL, is an
important risk factor for premature development of ischemic events.
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Introduction
Familial combined hyperlipidemia is a common famil-
ial lipid disorder characterized by a variable pattern of el-
evated levels of plasma cholesterol and/or triacylglyce-
rols and some apolipoproteins (e.g. apo B100)
1,2. It is
present in 10% to 20% of patients with premature coro-
nary artery disease. The genetic etiology of the disorder,
including the number of genes involved and the magni-
tude of their effects is unknown. Goldstein et al. gave the
designation »familial combined hyperlipidemia« to the
most common genetic form of hyperlipidemia identified
in a study of myocardial infarction survivors. The af-
fected individuals characteristically showed an elevation
in both cholesterol and triacylglycerols in the blood. The
combined disorder was shown to be distinct from familial
hypercholesterolemia (Fredrickson type II), and from fa-
milial hypertriacylglycerolemia1,3.
In this study, we investigated the extent of changes in
lipid and apolipoprotein (apo) serum levels as well as
atherogenous ratios in overweight men with familial
combined hyperlipidemia (FCHL) and with behavioral
pattern of excessive nutrition and low energy output.
These parameters are only rarely studied in both the
overweight and obese subjects with FCHL due to a low
incidence of the disease. Therefore, we compared lipid
and apolipoprotein serum levels observed in overweight
and obese subjects with those observed in the control
group. In the overweight subjects, apolipoprotein B100
(apo B100), apolipoprotein C-III (apo C-III) and apoli-
poprotein C-II (apo C-II) serum levels are evaluated only
very rarely.
Material and Methods
Forty-six subjects with FCHL were included in the
present study. These subjects (6.5%) were selected from a
group 710 re-screened adult clerks. Thirty-six of them
were overweight (5.1%) (OW) and 10 were obese (1.4%)
(OB). The control group included 17 men (2.4%) (CONTR)
with normal body weight and not suffering from any ge-
netic lipid disorder. The lipid and apolipoprotein serum
levels were assessed after overnight fasting. The genetic
causes of FCHL were not analyzed because of an exclu-
sively epidemiological character of the present study. The
presence of a hereditary disorder was concluded on the
basis of positive history of FCHL in the first line family
relatives using genealogical analysis. The criteria for
FCHL included serum levels of triacylglycerols higher
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than 2.3mmol/l and the total cholesterol higher than
6.2mmol/l after overnight fasting. Furthermore, LDL
cholesterol and the atherogenous ratios were also calcu-
lated. Daily food consumption was estimated on the basis
of questionnaires.
From the anthropometrical variables, the following
ones were determined: the body weight, body height, sur-
face of the body and body mass index (BMI kg/m2). BMI
we used as a criterion to distinguish among normal
weight, overweight and obesity4. Peripheral blood was
collected after overnight fasting (12 hour).
The total cholesterol (TC), triacylglycerols (TG) and
HDL-cholesterol (HDL-C) serum levels were assessed by
using standard Pliva-Lachema sets (Brno, Czech Repub-
lic). The LDL cholesterol (LDL-C) and non-HDL choles-
terol (non-HDL-C) serum levels were calculated using
the Friedewald´s5 and De Backer´s6 formula, respec-
tively. Vitamin C serum levels were assayed colorimet-
rically according to the method of Roe and Kuether7.
Apolipoprotein C-II and C-III serum levels were de-
termined by the method of radial immunoassay accord-
ing to Mancini8. Antibodies and standards purchased
from Daiichi Company (Tokyo, Japan) were used for
their determination. Serum levels of apo B100 were de-
tected by the electroimmunoassay according to the me-
thod of Curry9 using the standards and antibodies from
Behringwerke Company (Marburg, Germany).
Statistics
The data were analyzed using the univariate and
bivariate analysis, c2-test, Pearson correlation test as
well as partial correlation including canonical correlation
and McNemar's test. The relative risk according to Sato’s
computation was also calculated. The standard devia-
tion, median, percentile distribution, including the de-
termination of 95% confidence limit (CL95%), and confi-
dence interval (CI 5–95%) were calculated using the
descriptive statistics (p value <0.05 was accepted as sig-
nificant).
Results
The mean body weight and its CL95% were increased
by 2.43 kg/m2 and 3.1 kg/m2, respectively, in overweight
subjects, in comparison with the control group (11.8%).
The mean body mass index in the overweight subjects
was 27.8±1.4 kg/m2. The food intake in overweight and
obese subjects was compared to the control group and is
described in Table 1. The p value was calculated for OW
versus CONTR.
In overweight vs. control subjects, the mean serum
levels of TC, LDL-C, TG and non-HDL-C were signifi-
cantly increased by: 71.7%; 91.8%; 283.5%, and 104.2%
(p<0.001, Table 2), respectively. Serum levels of HDL-C
were significantly decreased by –5.8% (p<0.05). The
mean values of TC/HDL-C, LDL-C/HDL-C, and high
TG/low HDL-C known as the atherogenous ratios were
significantly increased by 82.4%; 103.8%; and 308.1%
(p<0.001), respectively. The mean value of the TG/apo
C-II atherogenous ratio was increased by 96.6% (p<
0.003). The mean value of the HDL-C/LDL-C athero-
genous ratio was significantly decreased by –50.8% (p<
0.01, Table 2).
The mean serum levels of apo B100 were significantly
increased not only the obese but also in overweight sub-
jects by 63.9% (p<0.001) and 58.5% (p<0.01), respec-
tively. In overweight subjects the apo C-II serum level
was increased by 93.3% and apo C-III by 161.8% (p<
0.001, Table 2).
In Table 3 we summarize the confidence intervals (CI
5–95%) of all variables studied. In the overweight sub-
jects and not only in the obese ones, differences of the TC
serum levels significantly increased by 69.8% (p<0.01).
Differences of the LDL-C, TG and non-HDL-C serum lev-
els in CL95% also significantly increased by 100.7%,
357.7% and 108.1% (p<0.001). Significant differences in
extent of 82.4% we detected in the TC/HDL-C ratio. Sig-
nificant differences in extent of 116.7% in CL95% we de-
tected in the LDL-C/HDL-C ratio.
In the overweight and obese men with FCHL we
found in CL95% against control group significantly high-
ly increased apo B100 (p<0.01), apo C-II (p<0.03; p<0.01)
and extremely high apo C-III serum levels (p<0.001).
The significant increases in triacylglycerol serum lev-
els after overnight fasting in overweight subjects are as-
sociated with increases in the BMI mean value (27.8±
1.4 kg/m2). Even more pronounced increases in TG se-
rum levels were observed in obese men. Elevation in tria-
cylglycerol serum levels is also associated with a signifi-
cant decrease in the mean, median and CL95% values of
HDL-C serum levels (p<0.05). The mean HDL-C/LDL-C
ratio significantly decreased in overweight subjects (p<
0.01). The differences in TG/HDL-C ratio values between
the overweight and obese subjects versus the control
group were extremely high (p<0.001).
Consistently with the changes in serum lipid levels,
apolipoprotein serum levels were also more significantly
elevated in obese men than in overweight subjects. In
8.7% of overweight subjects we detected significantly in-
creased apo B100 serum levels (p<0.01) but only a moder-
ate increase in TC. This finding (after overnight fasting)
is consistent with a picture of the hereditary hyper-
apobetalipoproteinemia10.
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TABLE 1
THE FOOD INTAKE AND NUTRITION STATE IN HEALTHY MEN
(CONTROL GROUP) AND OVERWEIGHT AND OBESE SUBJECTS
WITH FCHL
Food intake CONTR OW OB p
Glycides (%) 51 50–54 52–47 <0.05
Fat (%) 25 30–28 35–42 <0.01
Proteins (%) 24 20–18 13–11 <0.01
Fiber (g) 25–28 15–18 8–11 <0.01
CONTR – control group, OW – overweight subjects, OB – obese
subjects, p – probability
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TABLE 2
DISTRIBUTION OF THE LIPID AND APOLIPOPROTEIN SERUM LEVELS IN OVERWEIGHT AND OBESE SUBJECTS VERSUS CONTROLS
Biological
variables
OW OB CONTR OW vs. CONTR OB vs. CONTR
X±2SD MD X±2SD MD X±2SD MD
% p % p
BMI (kg/m2) 27.8±1.38 28.50 32.80±2.81 32.80 25.37±0.64 25.10 9.58 <0.05 29.29 <0,05
TC (mmol/l) 6.80±1.25 7.40 6.76±0.92 6.70 3.96±0.46 3.72 71.72 <0.001 70.71 <0.001
LDL-C (mmol/l) 4.20±1.27 5.10 3.86±1.06 3.94 2.19±0.26 2.04 91.78 <0.001 76.26 <0.001
HDL-C (mmol/l) 1.29±0.14 1.32 1.27±0.24 1.25 1.37±0.23 1.35 –5.84 <0.05 –7.30 <0.05
TG (mmol/l) 3.26±1.41 2.51 4.21±2.15 3.60 0.85±0.21 0.94 283.53 <0.001 395.29 <0.001
non-HDL-C (mmol/l) 5.41±1.27 6.10 5.49±0.87 5.49 2.65±0.29 2.50 104.15 <0.001 107.17 <0.001
TC/HDL-C 5.27±0.36 5.61 5.32±0.23 5.36 2.89±0.13 2.42 82.35 <0.001 84.08 <0.001
LDL-C/HDL-C 3.26±0.57 4.62 3.04±0.22 3.15 1.60±0.07 1.51 103.75 <0.001 90.00 <0.001
HDL-C/LDL-C 0.31±0.05 0.22 0.33±0.02 0.32 0.63±0.02 0.66 –50.79 <0.01 –47.62 <0.01
TG/HDL-C 2.53±0.74 1.90 3.31±0.90 2.88 0.62±0.04 0.70 308.06 <0.001 433.87 <0.001
TG/apo C-II 0.57±0.03 0.48 0.56±0.12 0.46 0.29±0.05 0.31 96.55 <0.003 93.10 <0.003
Apo B100/ LDL-C 25.40±3.79 17.05 28.58±2.26 28.43 30.73±0.65 30.88 –17.34 <0,05 –7.00 ns
apo B100 (mg/dl) 106.7±11.5 104.00 110.3±19.20 112.00 67.30±9.59 63.00 58.54 <0.01 63.89 <0.001
apo C-II (mg/dl) 5.74±2.00 5.20 7.58±1.75 7.80 2.97±0.18 3.00 93.27 <0.001 155.22 <0.001
apo C-II (mg/dl) 11.52±4.58 10.50 16.34±4.96 15.80 4.40±1.01 4.00 161.82 <0.001 271.36 <0.002
Vitamin C (µmol/l) 48.30±19.80 43.90 43.40±17.7 42.80 50.60±9.06 49.40 –4.55 ns –14.23 <0.05
OW – overweight subjects, OB – obese subjects, CONTR – control group, X – mean, SD – standard deviation, MD – median,
% – percentage differences, p – probability, ns – not significant
TABLE 3
DISTRIBUTION OF THE VARIABLES IN CI 5–95% INCLUDING DIFFERENCES IN THE CI95%















BMI (kg/m2) 25.10–29.40 30.09–36.80 24.58–26.30 11.79 <0.05 39.92 <0.02
TC (mmol/l) 4.77–7.93 5.45–8.52 3.44–4.67 69.81 <0.01 82.44 <0.01
LDL-C (mmol/l) 2.14–5.40 2.20–5.54 2.01–2.69 100.74 <0.001 105.95 <0.001
HDL-C (mmol/l) 1.22–1.60 0.98–1.64 1.08–1.72 –6.98 <0.05 –4.65 ns
TG (mmol/l) 2.31–5.63 2.37–6.22 0.62–1.23 357.72 <0.001 405.69 <0.001
Non-HDL-C (mmol/l) 3.31–6.45 4.21–7.18 2.36–3.10 108.06 <0.001 131.61 <0.001
TC/HDL-C 3.91–4.96 5.56–5.20 3.19–2.72 82.35 <0.01 91.18 <0.01
LDL-C/HDL-C 1.75–3.38 2.24–3.38 1.86–1.56 116.34 <0.001 116.54 <0.001
HDL-C/LDL-C 0.57–0.30 0.45–0.30 0.54–0.64 –53.13 <0.01 –53.13 <0.01
TG/HDL-C 1.89–3.52 2.42–3.79 0.57–0.72 388.89 <0.001 426.39 <0.001
TG/apo C-II 0.68–0.69 0.46–0.64 0.11–0.19 263.16 <0.003 236.84 <0.003
Apo B100/ LDL-C 44.09–23.00 38.18–25.54 29.45–31.71 –27.47 <0.05 –19.46 <0.05
Apo B100 (mg/dl) 94.35–124.20 84.0–141.50 59.20–85.30 45.60 <0.01 65.89 <0.01
Apo C-II (mg/dl) 3.45–8.21 5.18–9.75 5.40–6.46 27.09 <0.03 50.93 <0.01
Apo C-III (mg/dl) 6.27–17.44 8.93–24.00 3.17–6.03 189.22 <0.001 298.01 <0.001
Vitamin C (mmol/l) 23.50–76.68 20.20–74.58 36.86–67.70 13.26 <0.05 10.16 <0.05
N 10 36 16
OW – overweight subjects, OB – obese subjects, CONTR – control group, CI 5–95% – confidence interval, % – differences in CL95%,
p – probability, N – sample size, ns – not significant
U:\coll-antropolo\coll-antro-4-2006\Koprovicova.vp
7. prosinac 2006 10:38:06
Color profile: Disabled
Composite  150 lpi at 45 degrees
Not only in obese subjects but also in overweight men
we found significant correlation between the mean se-
rum levels of apo C-II and TG (r=0.33, p<0.04). This is a
sign of a tight metabolic relationship between the two
variables. Significant changes were also detected in the
TG/apo C-II ratio. Its value in CL95% was nearly three-
-times higher in obese and overweight subjects than in
the control group (p<0.003, Table 3).
The TG/HDL-C ratio shows a significant inverse cor-
relation with body mass index: r=–0.48 (p<0.002) in
overweight adults. In addition, the apo B100/LDL-C ratio
directly correlates with body mass index: r=0.47 (p<
0.002).
In Figure 1, a regression curve between apo C-II and
apo C-III is shown. This regression confirms a close rela-
tionship (p<0.01) between both variables in overweight
subjects. The correlation coefficient has the value: r=
0.41 (p<0.01) at the t-value: 2.63.
In Figure 2, a regression curve is shown between apo
C-III and HDL-C serum levels in overweight subjects. We
found an inverse relationship (p<0.01) between both
variables: r=–0.41 at the t-value: 6.367.
Discussion
Traditionally, in our geographic region, moderate body
weight excess is accepted as a sign of good health. This
misleading view, together with low social status and be-
havioural patterns of excessive eating are the main caus-
es of consuming a diet rich in fat (mainly saturated) and
poor in fruits and vegetables what is associated with a
body weight gain. Usually, the frequency of FCHL is rela-
tively low but is increased in overweight and obese sub-
jects11,12.
Over-nutrition deteriorates genetically caused diseas-
es of the lipid metabolism and this is evidently notable on
the mean and CL95% of the lipids and apolipoproteins
serum levels in overweight and obese subjects.
FCHL, as expressed by the changes in lipid and apoli-
poprotein serum levels, is besides genetic causes deterio-
rated also by an undesirable overeating. Significant ele-
vation in LDL-C and TG serum levels and raised TG/HDL
ratio after overnight fasting in overweight and obese
men demonstrates this relationship.
The HTG after overnight fasting, as a dominant find-
ing, is significantly expressed in overweight and obese
subjects by significant elevation of apo C-III serum lev-
els. This is an indirect signal of increased production of
triglyceride rich-lipoprotein (TG-RLPs) in the liver. Ele-
vated apo C-III serum levels are a reliable indirect sign of
the production of these large lipoprotein particles. The
TG-rich lipoprotein particles usually display a delayed
catabolism that is among other reasons also caused by a
direct inhibitory effect of apo C-III on the lipoprotein
lipase activity13,14. The TG-RLPs remnants are delayed
in circulation. Therefore they are more susceptible to ox-
idation. Simultaneously with their increased uptake to
by macrophages, they are deposits into the arterial wall.
This explains why these large lipoprotein particles are
atherogenous. The storage of TG in the adipocytes of
subcutaneous fat mass and predominantly viscerally is
the main cause of the body weight gain. However, accu-
mulation of TG associates with significant increase in
the apo C-III serum levels and their increased production
has a malicious impact on the catabolism of TG-RLPs.
Significant elevation of these variables potentiates the
risk of premature development of atherosclerosis leading
to an increased frequency of ischemic events in the heart,
brain and peripheral arteries15. Our data suggest that
not only obesity but also overweight, particularly in com-
bination with genetic causation of the FCHL, is associ-
ated with serious changes in lipid and apolipoprotein se-
rum levels2,12.
High TG-RLPs serum levels are an indirect marker of
endothelial dysfunction and through this pathway, they
amplify the global risk of ischemic events12. Therefore,
they play a significant role in triggering the early phases of
atherosclerosis andmainly atherothrombosis16,17,18 through
the pathways of plaque destabilization. Usually, HTG as-
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Fig. 1. Regression of the apo C-II and apo C-III
in the overweight (OW) subjects. r – correlation
coefficient, p – probability, N – sample size.
Fig. 2. Regression of the apo C-III and HDL-C
in the overweight (OW) subjects. r – correlation
coefficient, p – probability, N – sample size.
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sociates with low serum levels of HDL-C and is an impor-
tant clinical sign for dyslipidemia. The mechanism of this
type of disorder is sophisticated. In overweight and obese
subjects it is also potentiated by physical inactivity and
an intake of high amounts of fat, mainly saturated and
trans-fatty acids (Table 1). We assume that the signifi-
cantly increased value of TG/apo C-II ratio in CL95%
may be used as a useful indirect sign for delayed catabo-
lism of TG-RLPs (Table 3). It seems to be evident that
there is a significant disproportion between apo C-II and
triacylglycerol serum levels in subjects with overweight.
Nearly three times more increased apo C-III serum levels
against the control group means that activation of the li-
poprotein lipase by apo C-II is not satisfactorily efficient
in the lipolytic pathway of lipoprotein particles in spite of
its increased serum levels. With high probability we may
exclude genetic defects and apo C-II deficit in the over-
weight and obese subjects as one of the FCHL causes.
Generally, genetic defect in apo C-II is a very rare event
because mostly it is not compatible with survival.
Inhibitory effect of apo C-III on the activity of lipopro-
tein lipase and lipolysis of TG-RLPs is also experimen-
tally proven in transgenic mice19–21. Increased apo C-III
serum levels generally associate with production of TG-
RLPs via inhibition of their clearance22.
The high serum levels of apo C-III, as a marker of pre-
mature acute ischemic events, show a 3.4-times higher
ability to predict ischemic heart disease (IHD). Apo C-III
has a specific effect in patients with HTG because it de-
creases apo E-mediated remnant removal by apo E dis-
placement from VLDL particles23. This mechanism con-
tributes to HTG via blocking the binding of VLDL or IDL
particles on the LDLR-1, LDLR-2, eventually also VLDLR
and SR-BI receptor.
Not only obesity but also overweight closely associ-
ates with development of metabolic syndrome and has a
close relationship to the development of insulin resis-
tance24,25. This explains why also the overweight subjects
with genetically caused FCHL, increased blood pressure
and low HDL cholesterol, are threatened with premature
development of diabetes mellitus type 2, IHD, stroke and
atherosclerosis of the peripheral arteries.
We propose to introduce to the clinical practice the
calculation not only the LDL-C/HDL-C ratio in CL95%
but also the high TG/low HDL-C ratio for its high poten-
tial to predict premature development of IHD and of
stroke26,27.
HTG detected after overnight fasting in the over-
weight subjects with FCHL associates with a significant
increase in the apo B100 serum level. Significant elevation
in the apoB100/LDL-C ratio value is a valuable pathog-
nomic marker of a disproportion between apo B100 and
LDL-C serum levels, and an indirect sign of the LDL par-
ticles type B production, as well as a reliable predictor of
the premature development of IHD and myocardial in-
farction11,28,29. The TG serum levels equal or over 1.7
mmol/l in the overweight and obese subjects serve as an
indirect predictor of atherogenous LDL particles produc-
tion (ALP) and hence a cause of endothelial dysfunc-
tion16,30.
Significant depletion of HDL-C has a negative influ-
ence on its anti-inflammatory and anti-atherosclerotic
effects, from which thus the overweight subjects cannot
benefit31.
Very tight correlation between HTG (after overnight
fasting) and BMI in the overweight, as well as obese per-
sons indicates a very close metabolic association between
with deposition of TG into adipose tissue and over-nutri-
tion, high-energy intake and mainly low energy output.
It is the typical »acquired« behavioral pattern of the peo-
ple with sedentary lifestyle and low physical activity2,32,33.
Significant increase in the TG-RLPs in the obese and
overweight subjects frequently associates with serious
disorders in platelet aggregability. HTG triggers hyper-
activity of the platelets with a tendency to hypercoa-
gulation states. In addition, significant increase in the
plasma apo B100 levels predicts platelet-dependent throm-
bosis in patients with coronary artery disease34.
Significant depletion of vitamin C serum levels in the
HTG state in the overweight and obese subjects is an im-
portant sign of decreased anti-oxidative activity. Decreas-
ed vitamin C serum level is generally accepted as a pre-
disposition for higher oxidative risk17,35–37.
These changes detected in the overweight subjects
with FCHL indicate that not only obesity but also the
overweight is not a benign and tolerable biological, socio-
-cultural and socio-educational marker due to the above
mentioned reasons.
Conclusion
The FCHL as a genetically caused disease is deterio-
rated by a high-energy intake and sedentary lifestyle be-
cause of serious changes in the lipid and apolipoprotein
serum levels. In both the overweight and obese subjects,
the HTG detected after overnight fasting, is associated
with a significant increase in serum levels of apo C-III,
apo C-II, apo B100 and TG, as well as the HDL-C deple-
tion. Surprising is the finding of the increased apo C-II
serum levels because it is in contradiction to the tradi-
tional view. It might be a compensatory attempt to de-
crease high serum levels of triacylglycerols. Increased
apo C-III serum levels in association with HTG (after
overnight fasting) are a sign of TG-RLPs overproduction.
This is associated with delayed catabolism of lipoproteins
and triggering oxidation of lipoprotein particles and pro-
duction of small LDL atherogenous particles. Decreased
HDL-C serum levels indicate a lipid disorder what can be
extremely hazardous mainly in adults with FCHL and in-
creased body weight.
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PREHRANA, TJELESNA TE@INA I POGOR[AVANJE OBITELJSKI NASLJEDNE HIPERLIPIDEMIJE
S A @ E T A K
Razina lipida i apolipoproteina u serumu kao posljedica pretjeranog unosa hrane kod osoba s prekomjernom tje-
lesnom te`inom s obiteljski nasljednom hiperlipidemijom (FCHL) u usporedbi s pretilim osobama prou~ava se spo-
radi~no. U ovome istra`ivanju prou~avao se utjecaj prekomjerne tjelesne te`ine i pretilosti kod osoba s FCHL na razinu
serumskih lipida i apolipoproteina. U~esnici u ovom istra`ivanju bili su 36 mu{karaca s prekomjernom tjelesnom te-
`inom i 10 pretilih mu{karaca. 17 zdravih mu{karaca s normalnom razinom lipida ~inili su kontrolnu skupinu. Srednja
starosna dob svih ispitanika bila je 49±9 godina. Razine lipida i apolipoproteina u serumu odre|ivane su upotrebom
standardiziranih metoda. Tjelesna te`ina i kod mu{karaca s prekomjernom tjelesnom te`inom s FCHL, a ne samo kod
pretilih mu{karaca, povezana je s povi{enom razinom kolesterola i triglicerida u serumu (p<0.001), aterogenim pro-
mjenama, razinom apolipoproteina u serumu – apo C-III, apo C-II i apo B100 (p<0.001) te sa smanjenom razinom HDL
kolesterola u serumu (p<0.05). Metabolizam lipida kod mu{karaca FCHL pogor{ava se s visokim unosom energije u
odnosu na malu potro{nju. Prekomjerna tjelesna te`ina, a ne isklju~ivo pretilost povezana s FCHL, zna~ajan je rizi~ni
faktor za prerani nastanak ishemije.
J. Koprovi~ová et al.: Lipids and Apolipoproteins in Men with FCHL, Coll. Antropol. 30 (2006) 4: 777–782
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